Climb Bio, INC. (CLYM) — SEC Filings

Q: What are the key financial highlights for Climb Bio, INC.?

Key financial highlights for Climb Bio, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Climb Bio, INC.?

Key executives at Climb Bio, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Climb Bio, INC. stock?

Risk factors for Climb Bio, INC. (CLYM) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Climb Bio, INC.?

Forward-looking statements and predictions from Climb Bio, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Climb Bio, INC.. Recent DEFA14A filing on Apr 24, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Climb Bio, INC. on SEC EDGAR

Overview

Climb Bio, INC. (CLYM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Climb Bio, Inc. (CLYM) reported a net loss of $12.888 million for the three months ended September 30, 2025, a significant increase from the $8.895 million net loss in the prior-year period. For the nine months ended September 30, 2025, the net loss was $42.335 million, an improvement from the $65.4

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Climb Bio, INC. is neutral.

Filing Type Overview

Climb Bio, INC. (CLYM) has filed 3 DEFA14A, 20 8-K, 5 10-Q, 1 DEF 14A, 2 10-K, 3 SC 13G/A, 7 SC 13D/A, 2 SC 13G, 1 10-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (44)

DEFA14A Filing — DEFA14A · Apr 24, 2026
8-K Filing — 8-K · Dec 31, 2025
8-K Filing — 8-K · Dec 11, 2025
Climb Bio's Cash Dwindles Amid Soaring R&D Costs — 10-Q · Nov 6, 2025 Risk: high
Climb Bio, Inc. (CLYM) reported a net loss of $12.888 million for the three months ended September 30, 2025, a significant increase from the $8.895 million net
Climb Bio, Inc. Files 8-K — 8-K · Oct 17, 2025 Risk: low
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 17, 2025, reporting other events. The company, incorporated in Delaware with its pri
Climb Bio, Inc. Files 8-K on Officer/Director Changes — 8-K · Oct 1, 2025 Risk: medium
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on October 1, 2025, reporting on events as of September 30, 2025. The filing covers the departu
Climb Bio, Inc. Files 8-K — 8-K · Sep 29, 2025 Risk: low
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K on September 29, 2025, reporting on other events and financial statements. The company, incorpo
Climb Bio Narrows Loss to $29.4M Amid R&D Surge, Cash Dwindles — 10-Q · Aug 12, 2025 Risk: high
Climb Bio, Inc. (CLYM) reported a net loss of $29.447 million for the six months ended June 30, 2025, a significant improvement from the $56.586 million net los
Climb Bio Director Departs, Board Changes Announced — 8-K · Jun 18, 2025 Risk: medium
Climb Bio, Inc. announced on June 12, 2025, the departure of Director Dr. David S. Rickman. The company also reported on the election of new directors and chang
Climb Bio, Inc. Files 8-K on Security Holder Vote — 8-K · Jun 5, 2025 Risk: low
Climb Bio, Inc. filed an 8-K on June 5, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The company, formerly known as
Climb Bio Files Supplemental Proxy for 2025 Meeting — DEFA14A · May 23, 2025 Risk: low
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) is filing a supplemental proxy statement for its 2025 Annual Meeting of Stockholders. The filing, dated May
Climb Bio, Inc. Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
Climb Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Eliem Therapeutics, Inc., reported on its financial status,
Climb Bio Files Definitive Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed a definitive proxy statement (DEF 14A) on April 25, 2025, for its fiscal year ending December 31, 2024
Climb Bio Appoints New CEO, Board Shakeup — 8-K · Apr 1, 2025 Risk: medium
Climb Bio, Inc. announced on March 27, 2025, a series of executive and board changes. Dr. Jonathan M. Rothberg has been appointed as the new Chief Executive Off
Climb Bio, Inc. Files 8-K on Material Agreements — 8-K · Mar 25, 2025 Risk: low
On March 25, 2025, Climb Bio, Inc. filed an 8-K report detailing a material definitive agreement, results of operations, and financial condition. The company, f
10-K Filing — 10-K · Mar 25, 2025
Climb Bio, Inc. Files 8-K on Material Agreements — 8-K · Jan 10, 2025 Risk: medium
On January 8, 2025, Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) filed an 8-K report detailing a material definitive agreement, results of operations, an
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Climb Bio, Inc. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Climb Bio, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Eliem Therapeutics, Inc., reported on its financial activi
Climb Bio, Inc. (fka Eliem Therapeutics) Files 8-K — 8-K · Oct 15, 2024 Risk: low
On October 15, 2024, Climb Bio, Inc. filed an 8-K report. The filing indicates that the company was formerly known as Eliem Therapeutics, Inc. and changed its n
Climb Bio, Inc. Files 8-K with Corporate Updates — 8-K · Oct 2, 2024 Risk: low
Climb Bio, Inc. filed an 8-K on October 2, 2024, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements. The co
Eliem Therapeutics Reports Director Changes — 8-K · Aug 27, 2024 Risk: low
Eliem Therapeutics, Inc. filed an 8-K on August 23, 2024, reporting the departure of a director and the election of a new director. The filing also details comp
Eliem Therapeutics Names New Directors, Updates Exec Pay — 8-K · Aug 26, 2024 Risk: low
Eliem Therapeutics, Inc. announced on August 26, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elec
AI ETI LLC Amends Eliem Therapeutics Stake — SC 13D/A · Aug 16, 2024 Risk: medium
AI ETI LLC, an affiliate of Access Industries, has amended its Schedule 13D filing regarding Eliem Therapeutics, Inc. as of August 16, 2024. The filing indicate
SC 13G/A Filing — SC 13G/A · Aug 14, 2024
Eliem Therapeutics Files 8-K on Operations — 8-K · Aug 14, 2024 Risk: low
Eliem Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
SC 13G Filing — SC 13G · Jul 2, 2024
RA Capital Amends Eliem Therapeutics Stake Filing — SC 13D/A · Jul 1, 2024 Risk: medium
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and RA Capital Healthcare Fund, L.P., have amended their Schedule 13D filing regardin
Santhera Acquires Eliem Therapeutics for $10.5M — 8-K · Jun 27, 2024 Risk: medium
Eliem Therapeutics, Inc. announced on June 27, 2024, the completion of its acquisition by a subsidiary of Santhera Pharmaceuticals (Holding) AG. This transactio
Eliem Therapeutics Files 8-K for Security Holder Votes and Other Events — 8-K · Jun 26, 2024 Risk: low
Eliem Therapeutics, Inc. filed an 8-K on June 26, 2024, to report on matters submitted to a vote of its security holders and other events. The filing does not c
Eliem Therapeutics Files Proxy Statement Supplement — DEFA14A · Jun 14, 2024 Risk: low
Eliem Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on June 14, 2024, related to its 2024 Annual Meeting of Stockholders. This fil
Eliem Therapeutics Appoints New CMO, Directors — 8-K · Jun 12, 2024 Risk: medium
Eliem Therapeutics, Inc. announced on June 12, 2024, the appointment of Dr. Andrew R. Haskins as Chief Medical Officer and the election of Dr. Sarah L. Hough an
RA Capital Amends Eliem Therapeutics Stake — SC 13D/A · Jun 6, 2024 Risk: medium
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Ra HealthCare Fund, L.P., have amended their Schedule 13D filing for Eliem Therap
AI ETI LLC Amends Eliem Therapeutics Stake — SC 13D/A · May 17, 2024 Risk: medium
AI ETI LLC, an affiliate of Access Industries, has amended its Schedule 13D filing for Eliem Therapeutics, Inc. on May 17, 2024. The filing indicates a change i
RA Capital Management Amends Eliem Therapeutics Stake — SC 13D/A · May 17, 2024 Risk: medium
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and RA Capital Healthcare Fund, L.P., have amended their Schedule 13D filing regardin
Eliem Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
Eliem Therapeutics, Inc. (CLYM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Eliem Therapeutics, Inc. filed a 10-Q report for the quarterly per
SC 13G Filing — SC 13G · May 7, 2024
Eliem Therapeutics Files 10-K/A Amendment No. 1 for Fiscal Year Ended Dec 31, 2023 — 10-K/A · Apr 29, 2024 Risk: low
Eliem Therapeutics, Inc. (CLYM) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Eliem Therapeutics, Inc. filed an amendment (10-K/A) to i
RA Capital Adjusts Eliem Therapeutics Stake — SC 13D/A · Apr 12, 2024 Risk: medium
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Ra Health Care Fund, L.P., have amended their Schedule 13D filing regarding Eliem
Eliem Therapeutics Announces Officer Departure, Equity Sales — 8-K · Apr 11, 2024 Risk: medium
Eliem Therapeutics, Inc. announced on April 10, 2024, the departure of Dr. Andrew Reisner from his role as Chief Medical Officer. The company also disclosed inf
Eliem Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
Eliem Therapeutics, Inc. (CLYM) filed a Annual Report (10-K) with the SEC on March 28, 2024. Eliem Therapeutics, Inc. filed its annual report on Form 10-K for t
Eliem Therapeutics Relocates Principal Executive Offices — 8-K · Mar 19, 2024 Risk: low
Eliem Therapeutics, Inc. filed an 8-K on March 19, 2024, reporting an event on March 14, 2024. The filing indicates a change in the company's principal executiv
RA Capital Adjusts Eliem Therapeutics Stake — SC 13D/A · Mar 18, 2024 Risk: medium
RA Capital Management, L.P. and its affiliates, including Peter Kolchinsky and Ra HealthCare Fund, L.P., have amended their Schedule 13D filing regarding Eliem
BML Investment Partners Amends Eliem Therapeutics Stake — SC 13G/A · Feb 7, 2024
BML Investment Partners, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating a change in their beneficial ownership of Eliem Therapeutics, Inc.

Risk Profile

Risk Assessment: Of CLYM's 35 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Climb Bio, INC.'s most recent 10-Q filing (Nov 6, 2025):

Revenue: $0
Net Income: -$42.335M
EPS: -$0.63
Debt-to-Equity: 0.03
Cash Position: $25.803M
Operating Margin: N/A
Total Assets: $182.304M
Total Debt: $5.301M

Key Executives

Dr. David S. Rickman
Dr. Jonathan M. Rothberg
Dr. Marcella R. Constant
Mr. David E. R. Gray
Ms. Sarah E. Rothberg
Dr. Jeffrey W. Allen
Ms. Sarah L. Kelly
Dr. Andrew A. von Eschenbach
Dr. Robert J. Davies
Len Blavatnik
Alejandro Moreno
Langhorne S. Perrow
Peter Kolchinsky
Dr. Andrew R. Haskins
Dr. Sarah L. Hough

Industry Context

Climb Bio operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for rare diseases and unmet medical needs. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often hinges on innovation, clinical trial outcomes, and securing substantial funding.

Top Tags

13D-filing (5) · ownership-change (5) · corporate-update (4) · amendment (4) · pharmaceutical (3) · management-change (3) · filing (3) · proxy-statement (3) · 10-Q (3) · governance (3)

Key Numbers

Cash and cash equivalents: $25.803M — Decreased from $87.229M at Dec 31, 2024, indicating significant cash burn.
Net loss (Q3 2025): $12.888M — Increased from $8.895M in Q3 2024, showing widening losses.
Net loss (YTD Sep 2025): $42.335M — Improved from $65.481M YTD Sep 2024, primarily due to a non-recurring expense in 2024.
Research and development expenses (YTD Sep 2025): $32.975M — Increased significantly from $8.377M YTD Sep 2024, reflecting pipeline advancement.
Shares outstanding: 68,184,435 — As of October 31, 2025, indicating potential for future dilution.
Net loss per share (Q3 2025): $0.19 — Increased from $0.13 in Q3 2024.
Net loss per share (YTD Sep 2025): $0.63 — Improved from $1.57 YTD Sep 2024.
Gross proceeds from Private Placement: $120.0M — Received in June 2024, providing capital for operations.
SEC File Number: 001-40708 — Identifies the company's filing with the SEC.
IRS Employer Identification No.: 83-2273741 — Company's tax identification number.
Net Loss (H1 2025): $29.447M — Reduced from $56.586M in H1 2024
Research and Development Expenses (H1 2025): $23.902M — Increased from $2.137M in H1 2024
Acquired In-Process R&D (H1 2025): $0 — Down from $51.659M in H1 2024
Cash and Cash Equivalents (June 30, 2025): $22.682M — Decreased from $87.229M at Dec 31, 2024
Total Stockholders' Equity (June 30, 2025): $185.764M — Decreased from $211.881M at Dec 31, 2024

Related Companies

ELIEM · ELI

Frequently Asked Questions

What are the latest SEC filings for Climb Bio, INC. (CLYM)?

Climb Bio, INC. has 44 recent SEC filings from Feb 2024 to Apr 2026, including 20 8-K, 7 SC 13D/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CLYM filings?

Across 44 filings, the sentiment breakdown is: 1 bearish, 42 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Climb Bio, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Climb Bio, INC. (CLYM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Climb Bio, INC.?

Key financial highlights from Climb Bio, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CLYM?

The investment thesis for CLYM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Climb Bio, INC.?

Key executives identified across Climb Bio, INC.'s filings include Dr. David S. Rickman, Dr. Jonathan M. Rothberg, Dr. Marcella R. Constant, Mr. David E. R. Gray, Ms. Sarah E. Rothberg and 13 others.

What are the main risk factors for Climb Bio, INC. stock?

Of CLYM's 35 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 17 low-risk.

What are recent predictions and forward guidance from Climb Bio, INC.?

Forward guidance and predictions for Climb Bio, INC. are extracted from SEC filings as they are enriched.